Figure 2.
Comparison of the risk of motor complications and other adverse events associated with levodopa versus dopamine agonists. The length of the arrow reflects the extent of risk.
Note: *Ergot-derived dopamine agonists compared with levodopa.
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.